StockData
Corcept Therapeutics Inc logo

Corcept Therapeutics Inc (CORT) stock

CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30530% above fair value
$69.22−3.72 (-5.10%)

Close on Nov 16, 2026Market cap $7.48BP/E 164.8Yield –

Corcept Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Corcept Therapeutics's price to sales ratio was 10.4× on Nov 11, 2026, against 12.8× a year earlier. Over the last 5 years it ranged from 5.0× to 17.8×, with a median of 7.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202610.4×+4.7
2025Dec 31, 20255.6×−3.3
2024Dec 31, 20248.9×+0.8
2023Dec 29, 20238.2×+2.2
2022Dec 30, 20226.0×−1.1
2021Dec 31, 20217.1×−1.9
2020Dec 31, 20209.1×+3.8
2019Dec 31, 20195.2×−1.9
2018Dec 31, 20187.2×−8.7
2017Dec 29, 201715.9×+4.8
2016Dec 30, 201611.1×−1.1
2015Dec 31, 201512.2×−1.8
2014Dec 31, 201414.0×−28.0
2013Dec 31, 201342.1×–

More Corcept Therapeutics figures

See a number that looks wrong?